China National Medicines to Provide 400 Million Yuan Loans to Subsidiary

MT Newswires Live

Mar 20

China National Medicines (SHA:600511) plans to provide loans of up to 400 million yuan to its subsidiary, Sinopharm Holdings Beijing Tianxing Puxin Biopharmaceutical, according to a Shanghai bourse filing on Friday.

The loan, valid between May 9, 2026, and May 8, 2027, will support Tianxing Puxin's business development and help reduce financing costs.

The interest is based on the one-year loan prime rate and it is calculated daily and settled quarterly.

The pharmaceutical company's shares rose less than 2% during the midday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620204431"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620204431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620204431?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 12:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620204431","market":"sh","top_or_hot":-1,"title":"China National Medicines to Provide 400 Million Yuan Loans to Subsidiary","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600511\">China National Medicines</a> (SHA:600511) plans to provide loans of up to 400 million yuan to its subsidiary, Sinopharm Holdings Beijing Tianxing Puxin Biopharmaceutical, according to a Shanghai bourse filing on Friday.</p><p>The loan, valid between May 9, 2026, and May 8, 2027, will support Tianxing Puxin's business development and help reduce financing costs.</p><p>The interest is based on the one-year loan prime rate and it is calculated daily and settled quarterly.</p><p>The pharmaceutical company's shares rose less than 2% during the midday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China National Medicines to Provide 400 Million Yuan Loans to Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina National Medicines to Provide 400 Million Yuan Loans to Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-20 12:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600511\">China National Medicines</a> (SHA:600511) plans to provide loans of up to 400 million yuan to its subsidiary, Sinopharm Holdings Beijing Tianxing Puxin Biopharmaceutical, according to a Shanghai bourse filing on Friday.</p><p>The loan, valid between May 9, 2026, and May 8, 2027, will support Tianxing Puxin's business development and help reduce financing costs.</p><p>The interest is based on the one-year loan prime rate and it is calculated daily and settled quarterly.</p><p>The pharmaceutical company's shares rose less than 2% during the midday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620204431","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620204431","pubTimestamp":1773981789,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China National Medicines  plans to provide loans of up to 400 million yuan to its subsidiary, Sinopharm Holdings Beijing Tianxing Puxin Biopharmaceutical, according to a Shanghai bourse filing on Friday.The loan, valid between May 9, 2026, and May 8, 2027, will support Tianxing Puxin's business development and help reduce financing costs.The interest is based on the one-year loan prime rate and it is calculated daily and settled quarterly.The pharmaceutical company's shares rose less than 2% during the midday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600511":"国药股份","BK0175":"白马股","BK0082":"国资改革","BK0250":"批发","BK0010":"央企","BK0097":"医药电商","BK0028":"国家队","MDCO":"麦迪逊医药","BK0185":"二线龙头","NHLD":"National Holdings Corporation","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"中国医药将向子公司提供4亿元贷款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600511":0.9,"NHLD":1.5,"MDCO":1.5},"content_text":"China National Medicines (SHA:600511) plans to provide loans of up to 400 million yuan to its subsidiary, Sinopharm Holdings Beijing Tianxing Puxin Biopharmaceutical, according to a Shanghai bourse filing on Friday.The loan, valid between May 9, 2026, and May 8, 2027, will support Tianxing Puxin's business development and help reduce financing costs.The interest is based on the one-year loan prime rate and it is calculated daily and settled quarterly.The pharmaceutical company's shares rose less than 2% during the midday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}